Key facts
- This page summarizes Braden M. Leonard's Form 4 filing for Metacrine, Inc..
- 3 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 21 Dec 2022, 16:49.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Purchase
Purchase
Purchase
No transaction description listed
Additional SEC filing notes
Footnote F1
BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
Footnote F2
The shares were purchased in multiple transactions at $0.40. Full information regarding the number of shares purchased can be furnished to the SEC staff upon request.
Footnote F3
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.375 to $0.38. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request.
Footnote F4
The shares were purchased in multiple transactions at $0.40. Full information regarding the number of shares purchased can be furnished to the SEC staff upon request.